ArticleOncogene2002
Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 174 citations in OpenAlex.
- Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Trial
- Trial
- Review
- Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?Journal for immunotherapy of cancer · 2024Review
- Identification and validation of UBE2B as a prognostic biomarker promoting the development of esophageal carcinomas.Frontiers in immunology · 2024Article
- Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.Cardiovascular research · 2023Review
- Macrophage numbers in the marginal area of sarcomas predict clinical prognosis.Scientific reports · 2023Article
- The effect of normal, metaplastic, and neoplastic esophageal extracellular matrix upon macrophage activation.Journal of immunology and regenerative medicine · 2021Article
- Article
- Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma.Frontiers in oncology · 2021Review
- A Rational Insight into the Effect of Dimethyl Sulfoxide on TNF-α Activity.International journal of molecular sciences · 2020Article
- Esophageal extracellular matrix hydrogel mitigates metaplastic change in a dog model of Barrett's esophagus.Science advances · 2020Article
- Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival.Cancer immunology, immunotherapy : CII · 2020Article
- Article
- ENPP4 overexpression is associated with no recovery from Barrett's esophagus.International journal of clinical and experimental pathology · 2020Article
- Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche.Cancer management and research · 2020Review
- TRIM59 loss in M2 macrophages promotes melanoma migration and invasion by upregulating MMP-9 and Madcam1.Aging · 2019Article
- From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment.Cancer medicine · 2019Review
- In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence.BMC gastroenterology · 2019Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Barrett's metaplasia (BM) is an early lesion in the progression from oesophageal inflammation through dysplasia to the development of Barrett's adenocarcinoma (BA). Previous work indicates that BM and BA are associated with reduced E-cadherin expression and increased cytoplasmic/nuclear pools of its associated protein beta-catenin. beta-catenin participates in Wnt signalling and activates oncogene transcription by complexing with T-cells factors (TCF). One such oncogene is c-myc. We have previously shown that TNF-alpha can down-regulate E-cadherin expression. Here, we assess TNF-alpha expression in Barrett's metaplasia and examine if TNF-alpha can promote beta-catenin mediated transcription of oncogenes in a gastrointestinal model system. Employing immunohistochemistry and Western blot analysis of oesophageal tissue, epithelial expression of TNF-alpha increases with progression along the metaplasia-dysplasia-carcinoma sequence (P<0.001). beta-catenin mediated transcription was then assessed in TNF-alpha stimulated cell lines using the TOPFLASH reporter system whilst c-myc expression was assessed by real time PCR. In a columnar intestinal cell model, TNF-alpha induces c-myc expression which is induced via beta-catenin mediated transcription (P<0.05). This beta-catenin mediated transcription is independent of NF-kappaB activation. Thus, TNF-alpha is up-regulated in the progression of Barrett's oesophagus and beta-catenin mediated transcription of c-myc is a novel pathway whereby elevated levels of TNF-alpha may lead to oncogene transcription and altered biology in gastrointestinal epithelia and metaplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.